Antiviral Drugs - Romania

Romania

The projected revenue for the Antiviral Drugs market in Romania is estimated to reach US$64.70m in 2024.
It is expected to experience a steady annual growth rate (CAGR 2024-2029) of 2.03%, leading to a market volume of US$71.54m by 2029.
When compared globally, United States is predicted to generate the highest revenue in this market, with a projected revenue of US$30,640.00m in 2024.
Romania is experiencing a growing demand for antiviral drugs due to the increasing prevalence of viral infections in the country.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

Antiviral drugs have been in high demand globally due to the ongoing COVID-19 pandemic. Romania is no exception to this trend, with an increasing demand for antiviral drugs in the country.

Customer preferences: Customers in Romania have been showing a preference for antiviral drugs that are effective against a wide range of viruses. They are also looking for drugs that have minimal side effects and are affordable.

Trends in the market: The antiviral drugs market in Romania has been witnessing significant growth due to the COVID-19 pandemic. The demand for antiviral drugs has increased, and this trend is expected to continue in the near future. The market is expected to grow due to the increasing prevalence of viral infections and the development of new antiviral drugs.

Local special circumstances: Romania has a high prevalence of viral infections, including hepatitis B and C, HIV, and influenza. This has led to an increased demand for antiviral drugs in the country. Additionally, the COVID-19 pandemic has further fueled the demand for antiviral drugs. Romania has been one of the hardest-hit countries in Europe, and the government has been taking measures to control the spread of the virus. This has led to an increased demand for antiviral drugs in the country.

Underlying macroeconomic factors: The Romanian economy has been growing steadily in recent years, with a focus on developing the healthcare sector. The government has been investing in healthcare infrastructure and promoting the development of new drugs. This has led to the growth of the pharmaceutical industry in the country. Additionally, Romania has a large population, which has led to an increased demand for healthcare services, including antiviral drugs. The government has also been promoting the use of generic drugs, which has led to an increase in the availability of affordable antiviral drugs in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.